(Q40413945)

20 September 2017

1 reference

title

Molecular targets in the National Cancer Institute drug screen (English)

1 reference

20 September 2017

1

S E Bates

1 reference

20 September 2017

2

A T Fojo

1 reference

20 September 2017

J N Weinstein

3

1 reference

20 September 2017

T G Myers

4

1 reference

20 September 2017

M Alvarez

5

1 reference

20 September 2017

K D Pauli

6

1 reference

20 September 2017

B A Chabner

7

1 reference

20 September 2017

1 January 1995

1 reference

Journal of Cancer Research and Clinical Oncology

20 September 2017

1 reference

20 September 2017

121

1 reference

20 September 2017

9-10

1 reference

20 September 2017

495-500

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01197759

20 September 2017

0 references

cites work

Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.

1 reference

12 December 2020

Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data

1 reference

12 December 2020

Neural computing in cancer drug development: predicting mechanism of action

1 reference

12 December 2020

Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents.

1 reference

12 December 2020

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

1 reference

12 December 2020

Intensive treatment of acute leukemia in adults 70 years of age and older

1 reference

12 December 2020

Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. A Southwest Oncology Group Study

1 reference

12 December 2020

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

1 reference

12 December 2020

Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS.

1 reference

12 December 2020

A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia

1 reference

12 December 2020

P-glycoprotein mediates profound resistance to bisantrene.

1 reference

12 December 2020

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen

1 reference

12 December 2020

Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP).

1 reference

12 December 2020

Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action

1 reference

12 December 2020

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

1 reference

12 December 2020

Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study

1 reference

12 December 2020

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01197759

1 reference

20 September 2017

1 reference